Clinical Trial Update: Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) [Phase 2]

View source ↗

Summary

A Phase 2 trial update (ASPEN-04) evaluating evorpacept in combination with pembrolizumab and chemotherapy for advanced head and neck squamous cell carcinoma; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Evorpacept (ALX148)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: ALX Oncology Inc. | Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING